Published in Vasc Health Risk Manag on January 01, 2006
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. Int J Mol Sci (2016) 0.95
Microbubble and ultrasound radioenhancement of bladder cancer. Br J Cancer (2012) 0.94
The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci (2015) 0.91
Microfluidics: reframing biological enquiry. Nat Rev Mol Cell Biol (2015) 0.87
Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. Cancers (Basel) (2016) 0.86
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis. J Biol Chem (2015) 0.84
Soy and breast cancer: focus on angiogenesis. Int J Mol Sci (2015) 0.82
PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol (2016) 0.82
Anti-angiogenic effect of the total flavonoids in Scutellaria barbata D. Don. BMC Complement Altern Med (2013) 0.81
Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol (2014) 0.81
Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10. Oncoimmunology (2016) 0.81
Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget (2016) 0.80
Drug Carrier for Photodynamic Cancer Therapy. Int J Mol Sci (2015) 0.80
Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Adv Pharmacol (2015) 0.80
Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/β-catenin signaling axis. Sci Rep (2016) 0.80
Complement and macrophage crosstalk during process of angiogenesis in tumor progression. J Biomed Sci (2015) 0.78
Optical Coherence Tomography Angiography Characteristics of Iris Melanocytic Tumors. Ophthalmology (2016) 0.78
Using semi-quantitative dynamic contrast-enhanced magnetic resonance imaging parameters to evaluate tumor hypoxia: a preclinical feasibility study in a maxillofacial VX2 rabbit model. Am J Transl Res (2015) 0.78
Focus on Nintedanib in NSCLC and Other Tumors. Front Med (Lausanne) (2016) 0.77
Plants and their active compounds: natural molecules to target angiogenesis. Angiogenesis (2016) 0.77
Interplay between steroid hormone activation of the unfolded protein response and nuclear receptor action. Steroids (2016) 0.77
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review. Front Bioeng Biotechnol (2015) 0.77
A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J Cell Biol (2017) 0.76
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer. Oncotarget (2016) 0.76
Thalidomide and irradiation combination therapy increases substance P levels in vitro. Exp Ther Med (2011) 0.76
Structural Mechanisms and Drug Discovery Prospects of Rho GTPases. Cells (2016) 0.76
Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts. World J Gastroenterol (2007) 0.76
The effects of carbon nanotubes on lung and dermal cellular behaviors. Nanomedicine (Lond) (2014) 0.76
Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast. Oncol Lett (2016) 0.76
In Silico Investigation of Angiogenesis with Growth and Stress Generation Coupled to Local Extracellular Matrix Density. Ann Biomed Eng (2015) 0.76
Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk. Front Oncol (2016) 0.75
Chitosan-Based Multifunctional Platforms for Local Delivery of Therapeutics. Mar Drugs (2017) 0.75
Cancer Stem Cells in Moderately Differentiated Buccal Mucosal Squamous Cell Carcinoma Express Components of the Renin-Angiotensin System. Front Surg (2016) 0.75
En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study. World J Surg Oncol (2016) 0.75
The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners. Oncotarget (2016) 0.75
Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature. Br J Cancer (2017) 0.75
Tumor microvessel density-associated mast cells in canine nodal lymphoma. SAGE Open Med (2014) 0.75
Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med (2013) 0.75
Colon cancer-derived myofibroblasts increase endothelial cell migration by glucocorticoid-sensitive secretion of a pro-migratory factor. Vascul Pharmacol (2016) 0.75
Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother (2015) 0.75
RGD-conjugated two-photon absorbing near-IR emitting fluorescent probes for tumor vasculature imaging. Org Biomol Chem (2015) 0.75
CANCER CONUNDRUM. J Oral Maxillofac Pathol (2016) 0.75
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci (2017) 0.75
Immunohistochemical Expression of VEGF and Podoplanin in Uterine Cervical Squamous Intraepithelial Lesions. Dis Markers (2016) 0.75
Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog (2016) 0.75
Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press) (2016) 0.75
Proliferation, angiogenesis and differentiation related markers in compact and follicular-compact thyroid carcinomas in dogs. Open Vet J (2016) 0.75
Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective. Clin Exp Immunol (2015) 0.75
Marine Non-Glycosaminoglycan Sulfated Glycans as Potential Pharmaceuticals. Pharmaceuticals (Basel) (2015) 0.75
Understanding specific functions of PARP-2: new lessons for cancer therapy. Am J Cancer Res (2016) 0.75
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res (2016) 0.75
Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget (2016) 0.75
ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. Int J Biomed Sci (2017) 0.75
Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Sci Rep (2017) 0.75
SOX7 expression is critically required in FLK1-expressing cells for vasculogenesis and angiogenesis during mouse embryonic development. Mech Dev (2017) 0.75
Anti-tumor effects of the American cockroach, Periplaneta americana. Chin Med (2017) 0.75
Expression and Localization of Cathepsins B, D, and G in Two Cancer Stem Cell Subpopulations in Moderately Differentiated Oral Tongue Squamous Cell Carcinoma. Front Med (Lausanne) (2017) 0.75
The potential of cell sheet technique on the development of hepatocellular carcinoma in rat models. PLoS One (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 7.37
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev (1992) 5.50
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol (2002) 3.73
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med (1999) 2.62
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A (1990) 2.31
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 2.23
Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res (2001) 2.19
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A (1996) 2.07
Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation (1996) 2.04
Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res (1999) 2.03
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer (1999) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res (2000) 1.80
Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol (1993) 1.77
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Cancer Metastasis Rev (1996) 1.68
Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A (1998) 1.66
A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem (1998) 1.66
Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem (1998) 1.64
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Vascular endothelial growth factor. Eur J Cancer (1996) 1.58
The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem (2001) 1.55
Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res (1999) 1.45
Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci U S A (1996) 1.44
Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res (2001) 1.38
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia (2001) 1.37
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer (2004) 1.33
Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 1.32
Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer (2002) 1.31
Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer (2001) 1.30
Cancer: Out of air is not out of action. Nature (2003) 1.30
Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem (1999) 1.26
Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res (2002) 1.25
Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat (2001) 1.24
Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol (2000) 1.23
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res (1999) 1.20
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer (2003) 1.18
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol (1994) 1.15
Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology (2002) 1.14
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res (2000) 1.13
Two steps forward in the treatment of colorectal cancer. N Engl J Med (2004) 1.12
Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst (1982) 1.11
Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer (2000) 1.11
A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep (2004) 1.08
Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer (2001) 1.05
Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol (2001) 1.05
Molecular biology of upper gastrointestinal malignancies. Semin Oncol (2004) 1.05
Advances in the treatment of metastatic colorectal cancer. Oncologist (2005) 1.04
Angiostatin suppresses malignant glioma growth in vivo. Cancer Res (1998) 1.02
VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun (2003) 0.97
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J (1999) 0.96
Treatment of localized esophageal cancer. Semin Oncol (2004) 0.92
Splitting vessels: keeping lymph apart from blood. Nat Med (2003) 0.89
The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res (2004) 0.87
Preoperative chemoradiation for pancreatic cancer. Semin Oncol (2005) 0.78
An integrated approach for tailored treatment in breast cancer. Ann Oncol (2005) 0.77
Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary. Oncology (Williston Park) (2002) 0.76
Current research directions for locally advanced cervix cancer. Curr Oncol Rep (2003) 0.76
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol (2009) 2.16
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol (2008) 2.06
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Obstruction of St Jude Medical valves in the aortic position: histology and immunohistochemistry of pannus. J Thorac Cardiovasc Surg (2003) 1.99
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol (2004) 1.70
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol (2007) 1.66
CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J Biochem (2008) 1.55
Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol (2003) 1.50
Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol (2010) 1.43
Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res (2006) 1.42
A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol (2010) 1.39
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer (2004) 1.33
Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res (2005) 1.29
Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension (2007) 1.26
Report of the 16th follow-up survey of primary liver cancer. Hepatol Res (2005) 1.25
Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis (2002) 1.23
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol (2013) 1.23
Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res (2003) 1.23
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol (2012) 1.22
Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int (2007) 1.21
Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol (2002) 1.18
Focal cholesterol granuloma in the anterior mediastinum: [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and magnetic resonance imaging findings. J Thorac Oncol (2007) 1.16
Lower extremity nerve function in patients with lower extremity ischemia. Arch Intern Med (2006) 1.14
Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 cases. World J Gastroenterol (2012) 1.12
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther (2004) 1.12
Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation (2008) 1.12
Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol (2006) 1.12
Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One (2013) 1.11
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol (2009) 1.11
Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int (2007) 1.10
Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology (2008) 1.10
Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int (2010) 1.10
Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol (2010) 1.09
Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer (2007) 1.09
Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail (2008) 1.07
Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol (2004) 1.07
Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol (2007) 1.06
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05
N-terminal domains of CCN family 2/connective tissue growth factor bind to aggrecan. Biochem J (2009) 1.05
Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol (2006) 1.04
Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl (2011) 1.02
Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol (2002) 1.02
RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma. Int J Mol Med (2010) 1.01
Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis (2010) 1.01
Binding of glyceraldehyde-3-phosphate dehydrogenase to the cis-acting element of structure-anchored repression in ccn2 mRNA. Biochem Biophys Res Commun (2011) 1.00
Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. J Pediatr Surg (2007) 0.99
Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol Res (2010) 0.99
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol (2008) 0.97
A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol (2006) 0.97
Expression and localization of connective tissue growth factor (CTGF/Hcs24/CCN2) in osteoarthritic cartilage. Osteoarthritis Cartilage (2004) 0.97
SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion (2005) 0.97
Liver cell adenoma with malignant transformation: a case report. World J Gastroenterol (2003) 0.97
Histiocytic sarcoma of the parotid gland region. Pathol Int (2011) 0.97
Ductal carcinoma in situ arising in a benign phyllodes tumor: report of a case. Surg Today (2007) 0.96
Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary. J Obstet Gynaecol Res (2006) 0.96
Immunohistochemical expression of Mina53 and Ki67 proteins in human primary gingival squamous cell carcinoma. Kurume Med J (2006) 0.95
Unique hypervascular nodules in alcoholic liver cirrhosis: identical to focal nodular hyperplasia-like nodules? J Hepatol (2004) 0.95
A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol (2012) 0.94
Roles of PKC, PI3K and JNK in multiple transduction of CCN2/CTGF signals in chondrocytes. Bone (2006) 0.94
Fucoidan, a major component of brown seaweed, prohibits the growth of human cancer cell lines in vitro. Mol Med Rep (2011) 0.94
Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem (2005) 0.94
Splenic lymphangioma with papillary endothelial proliferation: a case report and review of the literature. Pathol Int (2003) 0.94
Hepatocellular carcinoma with an unusual neuroendocrine component. Pathol Int (2004) 0.93
High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci (2006) 0.93
Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett (2008) 0.93
Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors. Kurume Med J (2006) 0.93
Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol (2008) 0.93
X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. Oncol Rep (2007) 0.93
Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep (2007) 0.93
Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett (2003) 0.93
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother (2003) 0.92
Role of LRP1 in transport of CCN2 protein in chondrocytes. J Cell Sci (2012) 0.92